In fact, despite promising clinical findings of TNF-α inhibitors and other DMTs in T1D, fewer than 15% of T1D immunotherapies transition from phase 2 to phase 3 clinical trials in stage 3 T1D (4–12). The gene discussed is TNF; the disease is type 1 diabetes mellitus.